Cannabidiol-solution 50 mg/mL / 100 mg/mL / 200 mg/mL / 400 mg/mL

Cannabidiol is the most important and best-studied, non-psychoactive, natural cannabinoid of Indian hemp. In contrast to delta-9-tetrahydrocannabinol (THC), the substance has no intoxicating effect. Cannabidiol solutions are dosed individually for each patient and indication within a wide concentration range. Cannabidiol, unlike detla-9-tetrahydrocannabinol (THC), has no intoxicating effect and is not an anaesthetic.

Cannabidiol is prescribed according to an individual indication (prescription required) and has anticonvulsant, antianxiety and antiemetic effects, among others. It is also used in certain forms of childhood epilepsy, such as Dravet and Lennox-Gastaut syndromes.

With the supplementary delivery 2020/2, the NRF regulation 22.10. is extended by the concentration levels 200 mg/mL and 400 mg/mL. Thus, four concentrations are available and also higher single administrations can be realized with small amounts of liquid.

Due to the high photosensitivity of diluted cannabidiol solutions, light protection is recommended; this is ensured in the case of prefabricated stock by the prescribed storage in the refrigerator.

In the USA, the finished drug Epidyolex® (100 mg CBD/ml) is approved. In combination with clobazam in children two years and older. In July, the Committee for Medicinal Products for Human Use at the European Medicines Agency also voted in favor of approval for this indication.

1. https://www.ema.europa.eu/en/search/search?search_api_views_fulltext=cannabis